Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

[1]  M. Filetti,et al.  New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. , 2022, Cancer treatment reviews.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  S. Hancock,et al.  Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  M. Brunelli,et al.  Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. , 2021, Immunotherapy.

[5]  M. Remzi,et al.  Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis , 2021, Current opinion in urology.

[6]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[7]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[8]  G. Genovese,et al.  Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. , 2020, Clinical genitourinary cancer.

[9]  T. Bathala,et al.  Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. , 2020, Urologic oncology.

[10]  A. Ravaud,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma , 2020, Clinical Cancer Research.

[11]  T. Bathala,et al.  Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. , 2019, The oncologist.

[12]  A. Hartmann,et al.  Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options , 2019, Oncology Research and Treatment.

[13]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[14]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[15]  U. Vaishampayan.  Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer , 2018, Current Treatment Options in Oncology.

[16]  S. Signoretti,et al.  Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma , 2015, Cancer.

[17]  B. Escudier,et al.  Current and future strategies in nonclear-cell metastatic renal cell carcinoma , 2015, Current opinion in urology.

[18]  E. Porfiri,et al.  Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib. , 2014, Clinical genitourinary cancer.

[19]  R. Figlin,et al.  Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. , 2013, Urologic oncology.

[20]  R. Millikan,et al.  Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission. , 2013, Clinical genitourinary cancer.

[21]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[22]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[23]  A. Ravaud,et al.  Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma , 2011, Oncology.

[24]  E. Jonasch,et al.  Systemic therapy for sarcomatoid renal cell carcinoma , 2011, Expert review of anticancer therapy.

[25]  E. Jonasch,et al.  Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre , 2011, BJU international.

[26]  Ming Zhou,et al.  Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. , 2009, Journal of Clinical Oncology.

[27]  U. Vaishampayan,et al.  Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. , 2008, Urology.

[28]  J. Cheville,et al.  Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome , 2004, The American journal of surgical pathology.

[29]  S. Culine,et al.  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. , 2002, The Journal of urology.

[30]  J. Cheville,et al.  A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha. , 2011, Clinical advances in hematology & oncology : H&O.

[31]  J. Sinkovics,et al.  Chemoimmunotherapy of sarcomatoid renal cell carcinoma. , 1978, Medical and pediatric oncology.